How GLP-1 Receptor Agonists Work: Pancreas, Gut and Brain

GLP-1 receptor agonists are medicines that switch on the receptor for the gut hormone GLP-1, which acts on insulin, glucagon, stomach emptying and appetite.

Basics10 min read

Key takeaway

GLP-1 receptor agonists activate the GLP-1 receptor, a G-protein-coupled receptor first cloned in 1992. In the pancreas, activation raises insulin and lowers glucagon when glucose is elevated. In the gut, it slows stomach emptying, an effect that fades over time. Brain action is shown in animals; human studies link GLP-1 to lower food intake.

At a glance

Article typeBasics
Main guideWhat is semaglutide? Structure, research and FDA status
Regulatory statusFDA-approved“It is an FDA-approved prescription drug (Ozempic, Wegovy, Rybelsus)” (Where to buy semaglutide)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited10 in this article · 76 across 19 articles on Semaglutide
ProductSemaglutide product page

How GLP-1 receptor agonists work can be traced through one receptor and three main tissues. Labels summarize it briefly; cell, animal and human studies show how each effect was measured.

Quick answer: GLP-1 receptor agonists activate the same receptor as the natural hormone GLP-1 but last much longer in the body. FDA labels describe glucose-dependent insulin release, lower glucagon, delayed gastric emptying and reduced appetite. Tirzepatide also activates the GIP receptor. FDA approval applies to specific labeled medicines, not to research material.

What is a GLP-1 receptor agonist?

An agonist is a molecule that binds a receptor and switches it on. These medicines switch on the receptor for glucagon-like peptide-1 (GLP-1), a hormone the gut releases after eating. Vitrapep's article on what GLP-1 is covers the natural hormone.

The Ozempic label describes semaglutide as a GLP-1 analogue with 94% sequence homology to human GLP-1. It says semaglutide "selectively binds to and activates the GLP-1 receptor" (section 12.1).

Most medicines in the class are peptides. Not all are. The Foundayo label says orforglipron, a small molecule first approved in 2026, "binds to and activates the human GLP-1 receptor." Vitrapep's list of FDA-approved peptide medicines covers the peptide members.

The medicines differ from the hormone mainly in how long they last. The Ozempic label names albumin binding as the main reason, plus stabilization against the enzyme DPP-4. The Mounjaro label says tirzepatide's C20 fatty diacid "enables albumin binding and prolongs the half-life."

What is the GLP-1 receptor and where is it found?

In 1992, a University of Lausanne study cloned the receptor from rat pancreatic islets. Expressed in cultured cells, it bound GLP-1 with high affinity but did not bind glucagon, GIP or secretin (Thorens, 1992).

The receptor is 463 amino acids long and crosses the cell membrane seven times. Activating it switched on adenylate cyclase, the enzyme that makes cyclic AMP (cAMP). It belongs to a family of G-protein-coupled receptors that includes the secretin, calcitonin and parathyroid hormone receptors.

A 2014 study led by Novo Nordisk scientists mapped the receptor in monkey and human tissue (Pyke et al., 2014). It reported these sites.

  • Pancreas: mainly beta cells, with a weaker signal in acinar cells.
  • Gut: highest in Brunner's glands of the duodenum, lower in the stomach and in gut-wall nerve cells.
  • Heart: muscle cells of the sinoatrial node, the heart's natural pacemaker.
  • Kidney and lung: smooth muscle in the walls of small arteries.
  • No receptor was seen in primate liver or thyroid.

The brain is the other major site. The Wegovy label says the receptor "is present in several areas of the brain involved in appetite regulation."

What happens inside a cell when the receptor is switched on?

The receptor converts an outside signal into rising cAMP inside the cell. In beta cells, that signal works together with glucose rather than replacing it.

A 1993 study in rat beta cells showed how. Beta cells that did not respond to glucose became responsive with GLP-1. The authors called this "glucose competence" (Holz et al., 1993).

GLP-1 and glucose acted together to close potassium channels controlled by cell metabolism. Sulfonylurea drugs block the same channels. Closing them let calcium flow in, which triggers insulin release. This joint requirement is the cell-level basis for the "glucose-dependent" wording on labels.

The receptor can also recruit proteins called beta-arrestins, which are linked to pulling the receptor inside the cell. Agonists can favor one pathway over another, which researchers call biased agonism. Tirzepatide is a studied example.

How do GLP-1 receptor agonists affect insulin and glucagon?

The Ozempic label says semaglutide stimulates insulin and lowers glucagon, "both in a glucose-dependent manner." When glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited.

A 1993 human study showed what glucose dependence looks like. In a placebo-controlled design, 10 adults with poorly controlled type 2 diabetes received GLP-1 or placebo while fasting (Nauck et al., 1993). With GLP-1, insulin rose, glucagon fell and glucose reached normal fasting levels within four hours.

Once glucose was normal, insulin returned toward baseline and glucose stayed stable while GLP-1 was still being given. Placebo did not normalize glucose.

In the Ozempic label's type 2 diabetes data, fasting glucagon was 8% lower than with placebo. The post-meal glucagon response was 14 to 15% lower. During induced low blood sugar, semaglutide did not blunt the protective rise in glucagon.

Low blood sugar can still occur. The label warns of increased hypoglycemia risk, including severe hypoglycemia, when semaglutide is combined with insulin or a sulfonylurea.

Animal genetics support the receptor's role. Mice bred without it had higher glucose and lower insulin after an oral glucose challenge (Scrocchi et al., 1996).

How do they affect the stomach and gut?

GLP-1 receptor activation slows how fast food leaves the stomach. The Ozempic label counts "a minor delay in gastric emptying in the early postprandial phase" as part of how semaglutide lowers glucose.

The effect weakens with continued exposure. A 2011 study gave nine healthy volunteers GLP-1 or placebo over 8.5 hours (Nauck et al., 2011). Two liquid meals were served four hours apart. GLP-1 slowed emptying significantly more after the first meal than the second.

Pancreatic polypeptide, a marker of vagus nerve activity, fell after the first meal only. The authors concluded that the slowing fades rapidly at the level of vagal signaling, called tachyphylaxis. Glucose control after the second meal was weaker as a result.

The Mounjaro and Foundayo labels report a similar pattern: the delay is largest at the start of treatment and diminishes over time.

The effect also appears in label safety sections. The Ozempic label links delayed emptying to rare reports of pulmonary aspiration during general anesthesia or deep sedation. Those patients had food left in the stomach.

How do they act on the brain and appetite?

Human studies link GLP-1 to fullness and lower food intake. In a 1998 randomized, blinded crossover study, 20 healthy young men received GLP-1 or saline during test meals (Flint et al., 1998). GLP-1 increased satiety after a fixed breakfast and cut energy intake at a free-choice lunch by 12%.

Labels place this effect in the brain but rely on animal data for that step. The Wegovy label says animal studies show semaglutide "distributed to and activated neurons in brain regions involved in regulation of food intake." The Foundayo label says the same of orforglipron.

A 2014 rodent study traced one pathway (Secher et al., 2014). In mice, labeled liraglutide reached brain areas with a weaker blood-brain barrier. It bound neurons in the hypothalamic arcuate nucleus, and uptake required the GLP-1 receptor.

In mouse brain slices, GLP-1 directly stimulated neurons making POMC and CART, signals linked to fullness. It indirectly inhibited neurons making NPY and AgRP, signals linked to hunger. In rats, weight loss did not depend on receptors in the vagus nerve or area postrema.

In contrast, mice lacking the receptor had normal body weight and feeding (Scrocchi et al., 1996). Losing a natural signal and adding a long-acting agonist are different experiments.

Vitrapep's semaglutide mechanism article covers newer brain research.

Which findings come from cells, animals and people?

Table 1 sorts the studies above by evidence level.

Table 1

Which findings come from cells, animals and people

StudyEvidence levelModel and sizeMain finding
Thorens, 1992CellRat receptor in cultured cellsSeven-pass receptor coupled to adenylate cyclase
Holz et al., 1993CellRat beta cellsGLP-1 plus glucose closed potassium channels
Nauck et al., 1993Human10 adults with type 2 diabetesFasting glucose normalized; insulin fell back once it did
Scrocchi et al., 1996AnimalMice lacking the receptorGlucose intolerance; normal weight and feeding
Flint et al., 1998Human20 healthy men, crossover12% lower energy intake at lunch
Nauck et al., 2011Human9 healthy volunteersGastric slowing weaker after a second meal
Pyke et al., 2014TissueMonkey and human tissueReceptor in beta cells, sinoatrial node, arteries and gut
Secher et al., 2014AnimalRats and miceLiraglutide reached arcuate nucleus neurons

What do FDA labels say about each medicine's mechanism?

Section 12.1 of each label is the mechanism of action, and 12.2 is pharmacodynamics. Table 2 compares four current labels.

Table 2

What do FDA labels say about each medicine's mechanism

Label (ingredient)MoleculeReceptorsOther mechanism statementsGastric emptying
Ozempic (semaglutide)Peptide; albumin bindingGLP-1Glucose-dependent insulin and glucagon effects; kidney-risk mechanism not establishedMinor delay soon after meals
Wegovy (semaglutide)Same moleculeGLP-1Receptor in brain appetite areas; cardiovascular-risk mechanism not establishedDelayed
Mounjaro (tirzepatide)Peptide with C20 fatty diacidGIP and GLP-1First- and second-phase insulin enhanced; glucagon reducedLargest at the start, then diminishes
Foundayo (orforglipron)Small moleculeHuman GLP-1Brain appetite regions; animal neuron dataLargest at the start, then diminishes

How is tirzepatide's mechanism different?

Tirzepatide activates two receptors. The Mounjaro label says it activates "both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1" (section 12.1). GIP is the gut's second main incretin hormone.

A 2020 study by Eli Lilly scientists and academic partners measured how tirzepatide engages each receptor (Willard et al., 2020). Their occupancy estimates showed greater engagement of the GIP receptor, which they called an imbalanced profile.

At the GLP-1 receptor, tirzepatide favored cAMP production over beta-arrestin recruitment and drove less receptor internalization than GLP-1. In isolated islets, beta-arrestin 1 limited the insulin response to GLP-1 but not to tirzepatide. These are cell and tissue findings, and most authors were company employees.

See Vitrapep's tirzepatide mechanism article, tirzepatide complete guide and semaglutide complete guide for each molecule's trials.

Which side effects connect to the mechanism?

Labels list mostly digestive reactions. The Ozempic label lists nausea, vomiting, diarrhea, abdominal pain and constipation in at least 5% of patients. The Mounjaro label lists nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain.

In placebo-controlled trials, Mounjaro raised mean heart rate by 2 to 4 beats per minute, versus 1 on placebo. The primate receptor map found the receptor in the sinoatrial node, but the labels do not state a cause.

All four labels in Table 2 carry a boxed warning about thyroid C-cell tumors in rodents. A 2010 study found the receptor on rodent C-cells, where agonists raised calcitonin and caused C-cell overgrowth (Bjerre Knudsen et al., 2010). Primate C-cells had low receptor levels and released no calcitonin in response. Long-term effects in the human thyroid remain unknown, the authors wrote.

Orforglipron is not pharmacologically active in rats or mice and did not produce rodent tumors, according to its label. That label still says human relevance "has not been determined" for these receptor-dependent tumors.

In November 2026, FDA required a class-wide warning about NAION, a rare optic nerve condition (see FDA's GLP-1 eye-risk warning).

What is still unknown, and how does research material fit?

The Ozempic label says the mechanism of kidney-related risk reduction has not been established. The Wegovy label says the same for cardiovascular risk reduction.

FDA approval covers specific labeled products, and the statements above apply only to them. Research-grade material has no FDA-approved labeling. A research-use-only label does not make a compound legal or safe for people; see research peptides and human-use risks.

Frequently asked questions

Is a GLP-1 receptor agonist the same as GLP-1?

No. GLP-1 is a natural gut hormone. A GLP-1 receptor agonist is a medicine that activates the same receptor and lasts much longer.

Are all GLP-1 receptor agonists peptides?

No. Most are peptides, but orforglipron (Foundayo) is a small molecule that activates the human GLP-1 receptor.

Why is the insulin effect called glucose-dependent?

GLP-1 signaling amplifies insulin release when glucose is high. In a 1993 human study, insulin fell back toward baseline once glucose was normal.

Does the slowing of stomach emptying last?

It fades. A 2011 study found the delay weaker after a second meal, and two labels say it diminishes over time.

Do these medicines act directly on the brain?

Labels say GLP-1 receptors are present in appetite-regulating brain areas. Evidence that the medicines reach those neurons comes from animal studies.

Why do the labels carry a thyroid warning?

Rodent studies found receptor-dependent thyroid C-cell tumors. Primate C-cells have low receptor levels, but human relevance has not been determined.

What to know now

  • GLP-1 receptor agonists raise insulin and lower glucagon when glucose is elevated.
  • They slow stomach emptying, but the effect fades with continued exposure.
  • Direct brain action is shown in animals; human studies show lower food intake with GLP-1.

What we’re watching

  • Human studies that separate brain, gut and vagal nerve contributions to appetite changes.
  • Research on the mechanisms behind the cardiovascular and kidney outcomes named in labels.
  • Whether biased signaling at the GLP-1 receptor matters for clinical effects.

Also in the library

More for endocrine & metabolism

All 42 compounds for endocrine & metabolism

Sources: Thorens 1992, Proceedings of the National Academy of Sciences of the United States of America, 89; Holz 1993, Nature, 361; Nauck 1993, Diabetologia, 36; Scrocchi 1996, Nature Medicine, 2; Flint 1998, Journal of Clinical Investigation, 101; Bjerre Knudsen 2010, Endocrinology, 151; Nauck 2011, Diabetes, 60; Pyke 2014, Endocrinology, 155; Secher 2014, Journal of Clinical Investigation, 124; Willard 2020, JCI Insight, 5; Novo Nordisk 2026; Novo Nordisk 2026; Eli Lilly and Company 2026; Eli Lilly and Company 2026. All 14 citations

Back to the research library

References

  1. Thorens, B. (1992). Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proceedings of the National Academy of Sciences of the United States of America, 89(18), 8641-8645. https://pubmed.ncbi.nlm.nih.gov/1326760/
  2. Holz, G. G., 4th, Kühtreiber, W. M., & Habener, J. F. (1993). Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature, 361(6410), 362-365. https://pubmed.ncbi.nlm.nih.gov/8381211/
  3. Nauck, M. A., Kleine, N., Orskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993). Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia, 36(8), 741-744. https://pubmed.ncbi.nlm.nih.gov/8405741/
  4. Scrocchi, L. A., Brown, T. J., MaClusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996). Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nature Medicine, 2(11), 1254-1258. https://pubmed.ncbi.nlm.nih.gov/8898756/
  5. Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998). Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. Journal of Clinical Investigation, 101(3), 515-520. https://pubmed.ncbi.nlm.nih.gov/9449682/
  6. Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., et al. (2010). Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology, 151(4), 1473-1486. https://pubmed.ncbi.nlm.nih.gov/20203154/
  7. Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011). Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes, 60(5), 1561-1565. https://pubmed.ncbi.nlm.nih.gov/21430088/
  8. Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., et al. (2014). GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology, 155(4), 1280-1290. https://pubmed.ncbi.nlm.nih.gov/24467746/
  9. Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., et al. (2014). The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation, 124(10), 4473-4488. https://pubmed.ncbi.nlm.nih.gov/25202980/
  10. Willard, F. S., Douros, J. D., Gabe, M. B., Showalter, A. D., Wainscott, D. B., Suter, T. M., et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17), e140532. https://pubmed.ncbi.nlm.nih.gov/32730231/
  11. Novo Nordisk. (2026). OZEMPIC (semaglutide) prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  12. Novo Nordisk. (2026). WEGOVY (semaglutide) prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  13. Eli Lilly and Company. (2026). MOUNJARO (tirzepatide) prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  14. Eli Lilly and Company. (2026). FOUNDAYO (orforglipron) prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62